



PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

Ref: PDL: June: 2018/OC/01

Dated: 15.06.2018

The National Stock Exchange of India Limited
"Exchange Plaza", Banda Kurla Complex
Bandra East, Mumbai
Maharashtra

Sir

SUB: Non Compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 !

This is with reference to your letter No. NSE/LIST/FR/6565 dated 30 May, 2018 in regard to deficiency observed in the financial results for the Quarter/ year ended on 31 March, 2018 with respect to the following points:

1. Standalone Reconciliation of Profit and Loss not submitted.
2. Standalone Reconciliation of Equity not submitted.
3. Consolidated Reconciliation of Profit and Loss not submitted.
4. Consolidated Reconciliation of Equity not submitted.
5. Statement of unmodified opinion not submitted

In light of the above please find enclosed a scanned copy of the Standalone Reconciliation of Profit and Loss, Standalone Reconciliation of Equity, Consolidated Reconciliation of Profit and Loss , Consolidated Reconciliation of Equity and Statement of unmodified opinion for your kind perusal.

Kindly take note and oblige.

For & On Behalf of Parabolic Drugs Limited

Sincerely
For Parabolic Drugs Ltd

Authorised Signatory

Authorised Signatory



PARABOLIC DRUGS LTD.

PARABOLIC DRUGS LIMITED

CIN No. : L24231CH1996PLC017755.

Statement of Financial Results for the year ended 31st March 2018

1. Reconciliation of Profit / (Loss) reported in accordance with the Indian GAAP to total comprehensive Income in accordance with the Ind AS is given below:

Particulars	Year Ended 31.03.2018	Year Ended 31.03.2017	Qtr Ended 31.03.2018	Qtr Ended 31.03.2017	Year Ended 31.03.2018	Year Ended 31.03.2017
	Standalone		Standalone		Consolidated	
Profit / (Loss) after tax reported under previous I-GAPP	(57.00)	(108.07)	(14.69)	57.75	(57.55)	(108.09)
Actuarial (Gain) / Loss on employee defined benefit plans recognized in other Comprehensive Income	0.42	(0.21)	0.42	(0.05)	0.42	(0.21)
Net Profit / (Loss) after Tax as per Ind AS	(56.58)	(108.28)	(14.27)	57.70	(57.13)	(108.30)
Other Comprehensive Income as per Ind AS	(0.42)	0.21	(0.42)	0.05	(0.42)	0.21
Total Comprehensive Income as per Ind AS	(57.00)	(108.07)	(14.69)	57.75	(57.55)	(108.09)

2. Reconciliation of Equity reported in accordance with Indian GAP to equity in accordance with IND AS is given below

Particulars of Share holding	As at 31.03.2018	As at 31.03.2017	As at 31.03.2018	As at 31.03.2017
	Rs. In Cr.		Rs. In Cr.	
Total Equity as per India GAAP	(872.33)	(815.33)	(881.34)	(823.80)
Adjustments on account of Application of Ind AS	0.00	0.00	0.00	0.00
Total Equity as per Ind AS	(872.33)	(815.33)	(881.34)	(823.80)

For Parabolic Drugs Limited

Pranav Gupta
Managing Director



PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

Date: 29.05.2018

Ref. No.: PDL/SCY/MAY/2018

The National Stock Exchange of India Limited
"Exchange Plaza", Banda Kurla Complex
Bandra East, Mumbai
Maharashtra

Listing Compliance Cell
BSE Limited
PhirozeJeejeebhoy Towers
Dalal Street, Mumbai

Dear Sir,

Sub:- Declaration in respect of Audit Report with unmodified opinion for the financial year ended 31.03.2018.


Ref: Regulation 33(3) of SEBI (LODR) Regulation, 2015

With reference to the above, we hereby declare that the statutory auditors of the Company i.e --- V.K. Jindal & Associates Chartered Accountant (Reg FRN005244N) has issued their audit report with unmodified opinion on Audited Financial results (Standalone and consolidated) for the financial year ended 31.03.2018.

We request you to take this declaration on record.

Thanking you

For & On Behalf of Parabolic Drugs Limited

Sincerely
For Parabolic Drugs Ltd

Authorised Signatory
Authorised Signatory